Výsledky vyhledávání - "Miyuki Akutsu"

Akademický článek

Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies.

Autor: Nobuya Hiraoka, Jiro Kikuchi, Takahiro Yamauchi, Daisuke Koyama, Taeko Wada, Mitsuyo Uesawa, Miyuki Akutsu, Shigehisa Mori, Yuichi Nakamura, Takanori Ueda, Yasuhiko Kano, Yusuke Furukawa

Publikováno v: PLoS ONE, Vol 9, Iss 3, p e90675 (2014)

Bendamustine has shown considerable clinical activity against indolent lymphoid malignancies as a single agent or in combination with rituximab, but combination with additional anti-cancer drugs may be required for refractory and/or relapsed cases as

Externí odkaz: https://doaj.org/article/86532434e6ac4ca184c34d22daf3e22a

Zobrazit plný text záznamu

Akademický článek

Homopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome binding.

Autor: Jiro Kikuchi, Naoya Shibayama, Satoshi Yamada, Taeko Wada, Masaharu Nobuyoshi, Tohru Izumi, Miyuki Akutsu, Yasuhiko Kano, Kanako Sugiyama, Mio Ohki, Sam-Yong Park, Yusuke Furukawa

Publikováno v: PLoS ONE, Vol 8, Iss 4, p e60649 (2013)

The proteasome is a proteolytic machinery that executes the degradation of polyubiquitinated proteins to maintain cellular homeostasis. Proteasome inhibition is a unique and effective way to kill cancer cells because they are sensitive to proteotoxic

Externí odkaz: https://doaj.org/article/f4d1bbfc9fca4b3085df27986acf46d8

Zobrazit plný text záznamu

The Novel Orally Active Proteasome Inhibitor K-7174 Exerts Anti-myeloma Activity in Vitro and in Vivo by Down-regulating the Expression of Class I Histone Deacetylases

Autor: Yusuke Furukawa, Taeko Wada, Jiro Kikuchi, Daisuke Koyama, Masaharu Nobuyoshi, Yasuhiko Kano, Tohru Izumi, Satoshi Yamada, Miyuki Akutsu

Publikováno v: Journal of Biological Chemistry. 288:25593-25602

Bortezomib therapy is now indispensable for multiple myeloma, but is associated with patient inconvenience due to intravenous injection and emerging drug resistance. The development of orally active proteasome inhibitors with distinct mechanisms of a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d060bb10b5e58c60104d482e0009a58
https://doi.org/10.1074/jbc.m113.480574

Zobrazit plný text záznamu

Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma

Autor: Yusuke Furukawa, Tohru Izumi, Jiro Kikuchi, Taeko Wada, R Shimizu, Miyuki Akutsu, Yasuhiko Kano, Masaharu Nobuyoshi, Keiya Ozawa, Kaoru Noborio-Hatano, Kanae Mitsunaga

Publikováno v: Blood. 116:406-417

Bortezomib is now widely used for the treatment of multiple myeloma (MM); however, its action mechanisms are not fully understood. Despite the initial results, recent investigations have indicated that bortezomib does not inactivate nuclear factor-κ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10ca05018de28bef79b70e4aa83f1ae8
https://doi.org/10.1182/blood-2009-07-235663

Zobrazit plný text záznamu

Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines

Autor: Yusuke Furukawa, Y Matsuo, Hiroyuki Mano, T Odgerel, Hoang Anh Vu, Tohru Izumi, Keita Kirito, Yasuhiko Kano, Miyuki Akutsu, Yuko Sato, Saburo Tsunoda

Publikováno v: Leukemia. 21:1005-1014

FMS-like tyrosine kinase-3 (FLT3) is a new therapeutic target for acute myelocytic leukemia (AML), because FLT3 mutations are the most common genetic alterations in AML and are directly related to leukemogenesis. We studied cytotoxic interactions of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::846a71587cf54e4e65b3e963bc6301b0
https://doi.org/10.1038/sj.leu.2404593

Zobrazit plný text záznamu

Schedule-Dependent Interactions Between Pemetrexed and Cisplatin in Human Carcinoma Cell Lines In Vitro

Autor: Yasuhiko Kano, Yusuke Furukawa, Miyuki Akutsu, Tohru Izumi, Kiyoshi Mori, Saburo Tsunoda, Koichi Inoue, Hiroyuki Mano, Hiroyuki Kobayashi, Hirofumi Fujii, T Odgerel

Publikováno v: Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 16:85-95

The combination of pemetrexed and cisplatin shows good clinical activity against mesothelioma and lung cancer. In order to study the potential cellular basis for this, and provide leads as to how to optimize the combination, we studied the schedule-d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf1b72ea7d234cea5203662260109187
https://doi.org/10.3727/000000006783981215

Zobrazit plný text záznamu

Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines in vitro

Autor: Hiroyuki Mano, Yusuke Furukawa, T. Izumi, Yasuhiko Kano, Yasuo Yazawa, Hirofumi Fujii, Kiyoshi Mori, Miyuki Akutsu, Saburo Tsunoda

Publikováno v: Cancer Chemotherapy and Pharmacology. 54:505-513

Pemetrexed is a novel multitargeted antifolate with significant clinical activity against a variety of tumors. We studied the schedule-dependent cytotoxic effects of pemetrexed in combination with paclitaxel in vitro to improve our understanding of h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20ad66b5d94c0c1d4c46420bb6a0ecdb
https://doi.org/10.1007/s00280-004-0839-5

Zobrazit plný text záznamu

Schedule-dependent synergism and antagonism between methotrexate and cytarabine against human leukemia cell lines in vitro

Autor: Miyuki Akutsu, Saburo Tsunoda, Tohru Izumi, Yasuhiko Kano, Yusuke Furukawa, Ken Ohmine

Publikováno v: Leukemia. 16:1808-1817

Methotrexate (MTX) and cytarabine have been widely used for the treatment of acute leukemias and lymphomas for over 30 years. However, the optimal schedule of this combination is yet to be determined and a variety of schedules of the combination has

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb4cbae8bccb966add04d2ef29d573bc
https://doi.org/10.1038/sj.leu.2402573

Zobrazit plný text záznamu

Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies

Autor: Yasuhiko Kano, Miyuki Akutsu, Mitsuyo Uesawa, Daisuke Koyama, Takanori Ueda, Shigehisa Mori, Nobuya Hiraoka, Jiro Kikuchi, Yusuke Furukawa, Yuichi Nakamura, Taeko Wada, Takahiro Yamauchi

Publikováno v: PLoS ONE, Vol 9, Iss 3, p e90675 (2014)
PLoS ONE

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56c1ac09ab73dac136d808f94ccfc1e2
http://europepmc.org/articles/PMC3953125?pdf=render

Zobrazit plný text záznamu

In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis

Autor: Yusuke Furukawa, Yasuhiko Kano, L Bai, Miyuki Akutsu, K Kon, A Ichikawa, Saburo Tsunoda, K Suzuki

Publikováno v: Leukemia. 14:379-388

Fludarabine phosphate (2-F-ara-AMP) is an adenine nucleoside analogue that shows significant activity against chronic lymphocytic leukemia and indolent lymphoma. We assessed the cytotoxic interaction produced by the combination of the active metaboli

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de83b8ec234e4f4c1aee8f19d12454ca
https://doi.org/10.1038/sj.leu.2401684

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání